Last update Dec. 28, 2023
Niflumic acid is a cyclooxygenase-2 inhibitor, derived from nicotinic acid and the main metabolite of morniflumate. It has non-steroidal anti-inflammatory properties (NSAID), used to relieve inflammation, pain and edema in acute and chronic inflammatory conditions (rheumatoid arthritis, osteoarthritis and post-operative and post-traumatic events). Oral administration 3 to 4 times daily and typically as an ointment. Morniflumate is the morpholinoethyl ester of niflumic acid, with similar properties.
According to manufacturer's data, its excretion in breast milk is minimal, being the concentration reached in milk one hundredth of the plasma concentration. (AEMPS 2023)
Its high percentage of binding to plasma proteins makes it unlikely that significant amounts will pass into milk.
Given the scarcity of published data on this drug and breastfeeding, it may be safer to use anti-inflammatory drugs of proven safety in breastfeeding.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM